{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-031716","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2024-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.717694+00:00","generated_at":"2026-06-04T00:32:20.380617+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Estrella Immunopharma posts investor presentation; EB103 Phase I expected 1H 2024","bullets":["EB103 (CD19 ARTEMIS) IND cleared Q1 2023; Phase I trial targeted for 1H 2024 in r/r B-cell lymphoma.","IIS study: 6/12 CR (50%), 4/12 PR (33%), ORR 83%; no severe CRS; durable responses up to 23.2 months.","Partnered with Imugene (ASX:IMU) to combine CF33-CD19t oncolytic virus with EB103 for solid tumors.","Pipeline includes EB104 (CD19/CD22 dual-targeting) for lymphoma and EB201 for SLE (preclinical)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-031716","json":"https://secwatch.observer/filing/0001213900-24-031716.json","markdown":"https://secwatch.observer/filing/0001213900-24-031716.md","text":"https://secwatch.observer/filing/0001213900-24-031716.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024031716/0001213900-24-031716-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024031716/ea0203610-8k_estrella.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:32:20.380617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}